Acetyl-L-Carnitine · supplement
Evidence tier: weak
A mitochondrial and cognitive support compound, especially useful for diabetic nerve pain and age related mental decline.
Acetyl L carnitine is an acetylated form of carnitine. Carnitine's role in shuttling long chain fatty acids across the inner mitochondrial membrane for beta oxidation is textbook, undisputed biochemistry, and the acetyl group can also feed acetyl coenzyme A and, by extension, acetylcholine synthesis. That is the cholinergic and mitochondrial story the seed tells and the biochemistry is real. What is NOT established is that oral supplementation of an already replete person changes any of this in a way that alters symptoms. Mechanism is not outcome.
Weak. Diabetic neuropathy is the best studied use and it does not survive contact with Cochrane. The 2019 Cochrane review of acetyl L carnitine for diabetic peripheral neuropathy (PMID 31201734) pooled four randomised trials in 907 people and concluded, verbatim, that 'it is uncertain whether, in comparison with placebo, acetyl L carnitine reduces pain in people with diabetic peripheral neuropathy after 6 to 12 months; any effect may be present at doses greater than 1500 mg per day but not at lower doses'. The certainty of evidence for the pain outcome was rated VERY LOW. Data on functional impairment, sensory function and symptoms were absent or of very low certainty, and the safety evidence was too uncertain to draw conclusions. The conflict of interest picture is the part a buyer should know: ALL FOUR included trials involved acetyl L carnitine manufacturers, two were clearly manufacturer funded and the other two had at least one author who was a paid consultant to a manufacturer. There is no independent trial base here. Cognition is weaker still and it is trapped in a disease population. The positive meta analysis (Montgomery 2003) was in mild cognitive impairment and mild ALZHEIMER DISEASE at 1.5 to 3 g daily, not in healthy adults, and a Cochrane review published the same year concluded there was insufficient evidence to recommend clinical use for dementia (PMID 12804452). The most recent critical reviews say the effect, if real, is not likely to be large. Chronic fatigue, the third of the seed's three claims, has no comparable evidence base at all. On safety, Cochrane rated the adverse event evidence LOW certainty and declined to draw conclusions, so 'generally safe' is an assumption rather than a finding; what can be said is that no serious safety signal has emerged at conventional doses.
No authority sets one. Trial doses in the diabetic neuropathy literature run 1,500 to 3,000 mg daily in divided doses, and Cochrane specifically notes that any effect it could detect appeared only above 1,500 mg daily and not below it. The cognition trials used 1.5 to 3 g daily. The seed's 500 to 2,000 mg range therefore sits partly beneath the only dose band that showed anything.
500 to 2000 mg daily, split morning and midday.
Generally safe. May increase blood pressure medication effects.
Pregnancy: caution
Breastfeeding: caution
Active compounds: acetyl-L-carnitine
Remedies using Acetyl-L-Carnitine · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.